Glofitamab plus gemcitabine and oxaliplatin (GemOx) vs rituximab (R)-GemOx in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Efficacy and safety in patient subgroups
Year: 2025
Type: conference-abstract
Source: Blood
Authors: Haifaa Abdulhaq, William Townsend, Matthew Ku, Gareth P. Gregory, Jeremy Abramson, Huiqiang Huang, Huilai Zhang, Dok Hyun Yoon, Won-Seog Kim, Herve Ghesquieres, Mark Hertzberg, Qing-Yuan Zhang, Murali Kesavan, Estefania Mulvihill, Martine Joanna Kallemeijn, Richard Ta, Voleak Choeurng, Linda Lundberg, Christopher Fox
Institutions: University of California, San Francisco, University College London, The University of Melbourne, St Vincent's Hospital Melbourne, Monash Health, Monash University, Massachusetts General Hospital, Sun Yat-sen University Cancer Center, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Asan Medical Center, University of Ulsan, Samsung Medical Center, Sungkyunkwan University, Hospices Civils de Lyon, Hôpital Lyon Sud, UNSW Sydney, Prince of Wales Hospital, Harbin Medical University, Third Affiliated Hospital of Harbin Medical University, Roche (United Kingdom), Roche (Switzerland), University of Nottingham
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4417006194